Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) Per Share (Tables)

Net Income (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2024

The following tables set forth the computation of basic and diluted net income (loss) per share of common stock for the three and six months ended June 30, 2024 and June 30, 2023 (in thousands, except share and per share amounts):


	Three Months Ended June 30, 2024
	Common stock

Basic income per share:
Net income	$	98,463
Net income attributed to Series C Preferred Stock	(94,109)
Net income - basic	$	4,354
Weighted average shares	1,034,130
Basic net income per share	$	4.21

Diluted (loss) income per share:
Numerator:
Net income - basic	$	4,354
Change in fair value of warrant liability	(112,046)
Net loss - diluted	$	(107,692)

Denominator:
Effect of dilutive securities:
Weighted average shares - basic	1,034,130
Common shares issuable for warrants	6,619,172
Weighted average shares - diluted	7,653,302
Diluted net (loss) income per share	$	(14.07)


	Six Months Ended June 30, 2024
	Common stock

Basic income per share:
Net loss	$	(22,827)
Weighted average shares	946,756
Basic net loss per share	$	(24.11)

Diluted loss per share:
Numerator:
Net loss - basic	$	(22,827)
Change in fair value of warrant liability	(112,046)
Net loss - diluted	$	(134,873)

Denominator:
Effect of dilutive securities:
Weighted average shares - basic	946,756
Potentially dilutive shares	3,455,884
Weighted average shares - diluted	4,402,640
Diluted net loss per share	$	(30.63)

As the Company is in a net loss position as of the six months ended June 30, 2024, the two-class method of computing net loss per share results in no allocation of undistributed losses to participating securities.


	Three Months Ended June 30, 2023
	Common stock

Net loss	$	(8,193)
Weighted average shares	58,217
Basic and diluted net loss per share	$	(140.73)


	Six Months Ended June 30, 2023
	Common stock

Net loss	$	(18,148)
Weighted average shares	53,557
Basic and diluted net loss per share	$	(338.85)

Schedule of Anti-dilutive Securities

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the three and six months ended June 30, 2024 and 2023, as they could have been anti-dilutive:


	Three Months Ended		Six Months Ended
	June 30,		June 30,
	20243	2023	20243	2023
Stock options	156,940	7,706	156,940	7,706
Warrants on common stock1	148	17,237	148	17,237
Series C Preferred Stock (as-convertible to common stock)2	22,357,897	—	22,357,897	—

1 The weighted average number of common shares outstanding includes the weighted average outstanding pre-funded warrants for the period because their exercise price was nominal. The weighted average shares outstanding for the three and six months ended June 30, 2023 include the weighted average effect of 2,192 and 1,338 pre-funded warrants, respectively. There were no pre-funded warrants outstanding as of June 30, 2024.

2 Subject to stockholder approval, each share of the Company’s Series C Preferred Stock will automatically convert to 1,000 shares of common stock, subject to certain beneficial ownership limitations.

3 Pursuant to the Almata Transaction, the Company is required to pay potential development milestone payments to the former AlmataBio stockholders in cash, Avalo stock, or a combination thereof at the election of the former AlmataBio stockholders. In the event of share settlement, the number of Avalo shares delivered will vary based on the Company’s stock price. These additional shares are not included in the computation of basic and diluted net income (loss) per share for the three and six months ended June 30, 2024 pursuant to the guidance on contingently issuable shares.